Penile rehabilitation after radical prostatectomy: Where do we stand and where are we going?

被引:73
|
作者
Wang, Run
机构
[1] Univ Texas, Sch Med, Div Urol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源
JOURNAL OF SEXUAL MEDICINE | 2007年 / 4卷 / 04期
关键词
penile rehabilitation; erectile dysfunction; radical prostatectomy;
D O I
10.1111/j.1743-6109.2007.00482.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction. Postprostatectomy erectile dysfunction (ED) remains a serious quality-of-life issue. Recent advances in the understanding of the mechanism of postprostatectomy ED have stimulated great attention toward penile rehabilitation. Aim. This review presents and analyzes a contemporary series of the recent medical literature pertaining to penile rehabilitation therapy after radical prostatectomy (RP). Main Outcome Measures. The laboratory and clinical studies related to penile rehabilitation are analyzed. The validity of the methodology and the conclusion of the findings from each study are determined. Methods. The published and presented reports dealing with penile rehabilitation following RP in human and cavernous nerve injury in animal models are reviewed. Results. Exciting scientific discoveries have improved our understanding of postprostatectomy ED at the molecular level. The rationale for postprostatectomy penile rehabilitation appears to be logical according to animal studies. However, clinical studies have not consistently replicated the beneficial effects found in the laboratory studies. Currently available clinical studies are flawed due to short-term follow-up, small number of patients in the studies, studies with retrospective nature, or prospective studies without control. Rehabilitation programs are also facing a challenge with the compliance, which is critical for success for any rehabilitation program. At the present time, we do not have concrete evidence to recommend what, when, how long, and how often a particular penile rehabilitative therapy can be used effectively. Conclusions. Large prospective, multicentered, placebo-controlled trials with adequate follow-up are necessary to determine the cost-effective and therapeutic benefits of particular penile rehabilitative therapy or therapies in patients following the treatment of clinically localized prostate cancer. Until such evidence is available, it is difficult to recommend any particular penile rehabilitation program as a standard of practice.
引用
收藏
页码:1085 / 1097
页数:13
相关论文
共 50 条
  • [11] Endoluminal Bariatric Interventions : Where do we stand ? Where are we going ?
    Unlu, Ozan
    Okoh, Alexis
    Yilmaz, Bulent
    Roach, Emir C.
    Olayan, May
    Shatnawei, Abdullah
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2015, 78 (04) : 415 - 423
  • [12] Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?
    Luong, Tiffany
    Salabarria, Ann-Charlott
    Roach, Dwayne R.
    CLINICAL THERAPEUTICS, 2020, 42 (09) : 1659 - 1680
  • [13] Biomarkers for Alzheimer's Disease: Where Do We Stand and Where Are We Going?
    Villa, Chiara
    JOURNAL OF PERSONALIZED MEDICINE, 2020, 10 (04):
  • [14] Fatty liver and nonalcoholic steatohepatitis - Where do we stand and where are we going?
    Lonardo, A
    DIGESTIVE DISEASES, 1999, 17 (02) : 80 - 89
  • [15] Late Sodium Current of the Heart: Where Do We Stand and Where Are We Going?
    Horvath, Balazs
    Szentandrassy, Norbert
    Almassy, Janos
    Dienes, Csaba
    Kovacs, Zsigmond Mate
    Nanasi, Peter P.
    Banyasz, Tamas
    PHARMACEUTICALS, 2022, 15 (02)
  • [16] Living donor liver transplantation: where do we stand and where are we going?
    Lu, Hao
    Lu, Ling
    Zhang, Feng
    Zhai, Yuan
    Wang, Xuehao
    HEPATOBILIARY SURGERY AND NUTRITION, 2016, 5 (02) : 141 - 144
  • [17] Scoping review of brucellosis in Cameroon: Where do we stand, and where are we going?
    Laine, Christopher G.
    Wade, Abel
    Scott, H. Morgan
    Krecek, Rosina C.
    Arenas-Gamboa, Angela M.
    PLOS ONE, 2020, 15 (09):
  • [18] Squamous Cell Lung Cancer: Where Do We Stand and Where Are We Going?
    Hirsch, Fred R.
    ONCOLOGY-NEW YORK, 2013, 27 (09): : 914 - 915
  • [19] Pulmonary hypertension and beta blockers: where do we stand? Where are we going?
    Bugan, B.
    Roach, E. C.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2014, 18 (02) : 229 - 234
  • [20] The Role of Angiogenesis in Haemophilic Arthropathy: Where Do We Stand and Where Are We Going?
    Agapidou, Alexandra
    Stavrakis, Thomas
    Vlachaki, Efthymia
    Anagnostis, Panagiotis
    Vakalopoulou, Sophia
    TURKISH JOURNAL OF HEMATOLOGY, 2016, 33 (02) : 88 - 93